Tandem Diabetes Care (TNDM) Revenue & Revenue Breakdown
Tandem Diabetes Care Revenue Highlights
Latest Revenue (Y)
$747.72M
Latest Revenue (Q)
$331.03M
Main Geography (Y)
UNITED STATES
Tandem Diabetes Care Revenue by Period
Tandem Diabetes Care Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $747.72M | -6.68% |
| 2022-12-31 | $801.22M | 14.00% |
| 2021-12-31 | $702.80M | 40.89% |
| 2020-12-31 | $498.83M | 37.68% |
| 2019-12-31 | $362.31M | 97.05% |
| 2018-12-31 | $183.87M | 70.88% |
| 2017-12-31 | $107.60M | 27.72% |
| 2016-12-31 | $84.25M | 15.65% |
| 2015-12-31 | $72.85M | 46.51% |
| 2014-12-31 | $49.72M | 71.42% |
| 2013-12-31 | $29.01M | 1072.13% |
| 2012-12-31 | $2.47M | 100.00% |
| 2011-12-31 | - | - |
Tandem Diabetes Care generated $747.72M in revenue during NA 2023, up -6.68% compared to the previous quarter, and up 406.66% compared to the same period a year ago.
Tandem Diabetes Care Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $331.03M | 72.70% |
| 2024-03-31 | $191.67M | -2.60% |
| 2023-12-31 | $196.80M | 6.02% |
| 2023-09-30 | $185.62M | -5.25% |
| 2023-06-30 | $195.92M | 15.67% |
| 2023-03-31 | $169.38M | -23.18% |
| 2022-12-31 | $220.50M | 7.80% |
| 2022-09-30 | $204.55M | 2.14% |
| 2022-06-30 | $200.26M | 13.85% |
| 2022-03-31 | $175.91M | -16.23% |
| 2021-12-31 | $210.00M | 16.91% |
| 2021-09-30 | $179.63M | 4.35% |
| 2021-06-30 | $172.14M | 22.05% |
| 2021-03-31 | $141.04M | -16.08% |
| 2020-12-31 | $168.06M | 35.97% |
| 2020-09-30 | $123.60M | 13.15% |
| 2020-06-30 | $109.24M | 11.55% |
| 2020-03-31 | $97.93M | -9.66% |
| 2019-12-31 | $108.40M | 14.52% |
| 2019-09-30 | $94.66M | 1.50% |
| 2019-06-30 | $93.25M | 41.31% |
| 2019-03-31 | $66.00M | -13.39% |
| 2018-12-31 | $76.20M | 64.70% |
| 2018-09-30 | $46.26M | 35.57% |
| 2018-06-30 | $34.13M | 25.11% |
| 2018-03-31 | $27.28M | -32.31% |
| 2017-12-31 | $40.29M | 49.22% |
| 2017-09-30 | $27.00M | 26.61% |
| 2017-06-30 | $21.33M | 12.38% |
| 2017-03-31 | $18.98M | -34.36% |
| 2016-12-31 | $28.91M | 135.19% |
| 2016-09-30 | $12.29M | -46.52% |
| 2016-06-30 | $22.98M | 14.59% |
| 2016-03-31 | $20.06M | -31.12% |
| 2015-12-31 | $29.12M | 85.29% |
| 2015-09-30 | $15.72M | 0.06% |
| 2015-06-30 | $15.71M | 27.61% |
| 2015-03-31 | $12.31M | -31.19% |
| 2014-12-31 | $17.89M | 32.37% |
| 2014-09-30 | $13.51M | 31.78% |
| 2014-06-30 | $10.25M | 27.14% |
| 2014-03-31 | $8.07M | -21.27% |
| 2013-12-31 | $10.24M | 31.74% |
| 2013-09-30 | $7.78M | 40.67% |
| 2013-06-30 | $5.53M | 1.27% |
| 2013-03-31 | $5.46M | 141.85% |
| 2012-12-31 | $2.26M | 936.61% |
| 2012-09-30 | $217.73K | - |
Tandem Diabetes Care generated $331.03M in revenue during Q2 2024, up 72.70% compared to the previous quarter, and up 195.43% compared to the same period a year ago.
Tandem Diabetes Care Revenue Breakdown
Tandem Diabetes Care Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Jun 18 | Mar 18 |
|---|---|---|---|---|
| Supplies and Other | $113.88M | $105.53M | - | - |
| Pump | $107.88M | $87.29M | - | - |
| Complementary Products | - | - | $2.30M | $2.10M |
Tandem Diabetes Care's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Supplies and Other (51.35%), and Pump (48.65%).
Tandem Diabetes Care Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Non-US | $192.84M | $212.45M | $177.89M | $83.15M |
| UNITED STATES | $554.88M | $588.76M | $524.91M | $415.68M |
Tandem Diabetes Care's latest annual revenue breakdown by geography, as of Dec 23: UNITED STATES (74.21%), and Non-US (25.79%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-US | $65.20M | $61.91M | $45.88M | $55.40M | $53.42M | $38.14M | $54.72M | $58.51M | $54.59M | $44.62M | $49.11M | $46.52M | $44.56M | $37.70M |
| UNITED STATES | $156.71M | $129.76M | $150.91M | $130.22M | $142.50M | $131.24M | $165.78M | $146.03M | $145.67M | $131.28M | $160.88M | $133.11M | $127.58M | $103.34M |
Tandem Diabetes Care's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (70.62%), and Non-US (29.38%).
Tandem Diabetes Care Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ABT | Abbott Laboratories | $40.11B | $10.38B |
| MDT | Medtronic | $32.36B | $7.92B |
| SYK | Stryker | $20.50B | $5.42B |
| ALGN | Align | $3.86B | $1.03B |
| DXCM | DexCom | $3.62B | $1.00B |
| PODD | Insulet | $1.70B | $488.50M |
| PEN | Penumbra | $1.06B | $299.40M |
| TNDM | Tandem Diabetes Care | $747.72M | $331.03M |
| SWAV | ShockWave Medical | $730.23M | $218.81M |
| INSP | Inspire Medical Systems | $624.80M | $195.88M |
| PACB | Pacific Biosciences of California | $200.52M | $38.81M |
| NNOX | Nano-X Imaging | $9.90M | $2.55M |
TNDM Revenue FAQ
What is Tandem Diabetes Care’s yearly revenue?
Tandem Diabetes Care's yearly revenue for 2023 was $747.72M, representing a decrease of -6.68% compared to 2022. The company's yearly revenue for 2022 was $801.22M, representing an increase of 14.00% compared to 2021. TNDM's yearly revenue for 2021 was $702.8M, representing an increase of 40.89% compared to 2020.
What is Tandem Diabetes Care’s quarterly revenue?
Tandem Diabetes Care's quarterly revenue for Q2 2024 was $331.03M, a 72.70% increase from the previous quarter (Q1 2024), and a 68.96% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $191.67M, a -2.60% decrease from the previous quarter (Q4 2023), and a 13.16% increase year-over-year (Q1 2023). TNDM's quarterly revenue for Q4 2023 was $196.8M, a 6.02% increase from the previous quarter (Q3 2023), and a -10.75% decrease year-over-year (Q4 2022).
What is Tandem Diabetes Care’s revenue growth rate?
Tandem Diabetes Care's revenue growth rate for the last 3 years (2021-2023) was 6.39%, and for the last 5 years (2019-2023) was 106.38%.